Abstract:Most platinum group-based cyclometalated neutral and cationic anticancer complexes with the general formula [(C<^>N)(2)Ir(XY)](0/+) (neutral complex: XY = bidentate anionic ligand; cationic complex: XY = bidentate neutral ligand) are notable owing to their intrinsic luminescence properties, good cell permeability, interaction with some biomolecular targets and unique mechanisms of action (MoAs). We herein synthesized a series of neutral and cationic amine-imine cyclometalated iridium(iii) complexes using Schiff base ligands with sp(2)-N/sp(3)-N N<^>NH2 chelating donors. The cyclometalated iridium(iii) complexes were identified by various techniques. They were stable in aqueous media, displayed moderate fluorescence and exhibited affinity toward bovine serum albumin (BSA). The complexes demonstrated promising cytotoxicity against lung cancer A549 cells, cisplatin-resistant lung cancer A549/DDP cells, cervical carcinoma HeLa cells and human liver carcinoma HepG2 cells, with IC50 values ranging from 9.98 to 19.63 mu M. Unfortunately, these complexes had a low selectivity (selectivity index: 1.62-1.98) towards A549 cells and BEAS-2B normal cells. The charge pattern of the metal center (neutral or cationic) and ligand substituents showed little influence on the cytotoxicity and selectivity of these complexes. The study revealed that these complexes could target mitochondria, cause depolarization of the mitochondrial membrane, and trigger the production of intracellular ROS. Additionally, the complexes were observed to induce late apoptosis and perturb the cell cycle in the G(2)/M or S phase in A549 cells. Based on these results, it appears that the anticancer efficacy of these complexes was predominantly attributed to the redox mechanism.

Cyclometalated Iridium(iii) Complexes As Mitochondria-Targeted Anticancer Agents.

Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents

Cyclometalated Iridium(iii)-Guanidinium Complexes As Mitochondria-Targeted Anticancer Agents.

Mitochondria-targeted Phosphorescent Cyclometalated Iridium(iii) Complexes: Synthesis, Characterization, and Anticancer Properties

Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.

Cyclometalated Iridium(III) Complexes As Mitochondria-targeting Photosensitizers Against Cisplatin-resistant Cells.

Mitochondria-targeted Neutral and Cationic Iridium(iii) Anticancer Complexes Chelating Simple Hybrid Sp2-N/sp3-n Donor Ligands.

Cyclometalated Iridium(III) Complexes as Mitochondria‐targeting Photosensitizers against Cisplatin‐resistant Cells <sup>†</sup>

Mitochondria-targeted Cyclometalated Iridium-Β-carboline Complexes As Potent Non-Small Cell Lung Cancer Therapeutic Agents

Mitochondria-targeted Cyclometalated Iridium (III) Complexes: Dual Induction of A549 Cells Apoptosis and Autophagy.

Anticancer Cyclometalated Iridium(III) Complexes with Planar Ligands: Mitochondrial DNA Damage and Metabolism Disturbance.

Cyclometalated iridium(iii) N-heterocyclic carbene complexes as potential mitochondrial anticancer and photodynamic agents.

Ester-Modified Cyclometalated Iridium(Iii) Complexes As Mitochondria-Targeting Anticancer Agents

Cyclometalated Iridium(iii) Complexes Induce Mitochondria-Derived Paraptotic Cell Death and Inhibit Tumor Growth in Vivo.

Phosphorescent Iridium(iii)-Bis-n-heterocyclic Carbene Complexes As Mitochondria-Targeted Theranostic and Photodynamic Anticancer Agents.

Novel Lysosome-Targeted Cyclometalated Iridium(III) Anticancer Complexes Containing Imine-N-heterocyclic Carbene Ligands: Synthesis, Spectroscopic Properties and Biological Activity

Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer and antibacterial agents to induce both autophagy and apoptosis

Exploring anticancer efficiency of mitochondria-targeted cyclometalated iridium(III) complexes

Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

Dual-Functional Cyclometalated Iridium Imine Nhc Complexes: Highly Potent Anticancer And Antimetastatic Agents

Lysosome-Targeted Cyclometalated Iridium (Iii) Anticancer Complexes Bearing Phosphine-Sulfonate Ligands